

**CRITERIA FOR PRIOR AUTHORIZATION**

Entyvio® (vedolizumab)

**PROVIDER GROUP** Pharmacy  
Professional**MANUAL GUIDELINES** The following drug requires prior authorization:  
Vedolizumab (Entyvio)**CRITERIA FOR ULCERATIVE COLITIS (UC)** (Must meet all of the following):

- Patient must have a diagnosis of moderately to severely active ulcerative colitis
- Patient must be 18 years of age or older
- Evaluation for latent TB with TB skin test prior to initial prior authorization approval
- Must be prescribed by or in consultation with a gastroenterologist
- Patient has not taken another biologic agent (see attached table) in the past 30 days
- The patient had one of the following:
  - An inadequate response with, lost response to, or was intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator
  - An inadequate response with, was intolerant to, or demonstrated dependence on corticosteroids
  - The patient has used a conventional ulcerative colitis therapy (see attached table) OR there is documentation of inadequate response, contraindication, allergy, or intolerable side effects to a conventional ulcerative colitis therapy (see attached table)

**CRITERIA FOR CROHN'S DISEASE (CD)** (Must meet all of the following):

- Patient must have a diagnosis of moderately to severely active Crohn's disease
- Patient must be 18 years of age or older
- Evaluation for latent TB with TB skin test prior to initial prior authorization approval
- Must be prescribed by or in consultation with a gastroenterologist
- Patient has not taken another biologic agent (see attached table) in the past 30 days
- The patient had one of the following:
  - An inadequate response with, lost response to, or was intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator
  - An inadequate response with, was intolerant to, or demonstrated dependence on corticosteroids
  - The patient has used a conventional Crohn's disease therapy (see attached table) **OR** there is documentation of inadequate response, contraindication, allergy, or intolerable side effects to a conventional Crohn's disease therapy (see attached table)

**LENGTH OF APPROVAL** 12 months

---

 DRUG UTILIZATION REVIEW COMMITTEE CHAIR

---

 PHARMACY PROGRAM MANAGER  
 DIVISION OF HEALTH CARE FINANCE  
 KANSAS DEPARTMENT OF HEALTH AND ENVIRONMENT

---

 DATE

---

 DATE

Biologic Agents	
Generic Name	Brand Name
Abatacept	Orencia®
Adalimumab	Humira®, Amjevita®
Alefacept	Amevive®
Anakinra	Kineret®
Certolizumab	Cimzia®
Golimumab	Simponi®
Infliximab	Remicade®, Inflectra®
Natalizumab	Tysabri®
Rituximab	Rituxan®
Tocilizumab	Actemra®
Ustekinumab	Stelara®
Secukinumab	Cosentyx®
Etanercept	Enbrel®, Erelzi®
Canakinumab	Ilaris®

Conventional Crohn's Disease Therapies	
Generic Name	Brand Name
Azathioprine	Azasan®, Imuran®
Budesonide	Entocort®
Cortisone	Cortone®
Dexamethasone	Decadron®, Dexone®, Hexadrol®, Baycadron®, DexPak®, Zema-Pak®
Hydrocortisone	Hydrocortone®, Cortef®
Mercaptopurine	Purinethol®
Mesalamine	Apriso®, Lialda®, Cariasa®, Pentasa®, Asacol®, Rowasa®, SF-Rowasa®, Fiv-Asa®
Methotrexate	Trexall®, Rheumatrex®
Methylprednisone	Medrol®, MethylPred®, Meprolone UniPak®
Prednisolone	Prelone®, MilliPred®, OraPred®, VeriPred®, Bubbli-Pred®, PediaPred®
Prednisolone/Peak Flow Meter	AsmaPred Plus®
Prednisone	Orasone®, Meticorten®, SteraPred®, Deltasone®, Prenicen-M®
Sulfasalazine	Azulfidine®, Sulfazine®

Conventional Ulcerative Colitis Therapies	
Generic Name	Brand Name
Balsalazide	Colazal®
Budesonide	Uceris®
Cortisone	Cortone®
Dexamethasone	Decadron®, Dexone®, Hexadrol®, Baycadron®, DexPak®, Zema-Pak®
Hydrocortisone	Hydrocortone®, Cortef®
Mesalamine	Apriso®, Lialda®, Canasa®, Pentasa®, Asacol®, Rowasa®, SF-Rowasa®, Fiv-Asa®
Methylprednisolone	Medrol®, Meprolone UniPak®, MethylPred®
Prednisolone	Prelone®, MilliPred®, OraPred®, VeriPred®, PediaPred®, Bubbli-Pred®
Prednisolone/Peak Flow Meter	AsmalPred Plus®
Prednisone	Orasone®, Meticorten®, SteraPred®, Deltasone®, Prednicen-M®
Sulfasalazine	Azulfidine®, Sulfazine®